secwatch.observer — SEC 8-K summary
======================================

Issuer:     IMMUNIC, INC. (IMUX)
CIK:        0001280776
Form:       8-K
Filed at:   2026-05-19T11:00:48+00:00
Accession:  0001193805-26-000645
Event type: leadership
Sentiment:  positive
Materiality: 0.70
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunic appoints Michael W. Bonney as Chair of Board; MS expertise ahead of trial readouts
--------------------------------------------------------------------------------

- Michael W. Bonney appointed Chair effective May 16, 2026; Simona Skerjanec transitions from Interim Chair to board member.
- Bonney brings 30+ years biopharma experience, including Avonex launch at Biogen and CEO of Cubist (acquired by Merck for $9.5B).
- Board size increased from 9 to 10; Bonney received option grant for 100k shares vesting over 3 years.
- Company advances vidofludimus calcium toward phase 3 ENSURE readout in relapsing MS and planned PPMS program.
- Simona Skerjanec remains as board member after transitioning from Interim Chair.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1280776/000119380526000645/0001193805-26-000645-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1280776/000119380526000645/e665479_8k-immunic.htm
  HTML page:      https://secwatch.observer/filing/0001193805-26-000645

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer